Importantly, the histone deacetylase inhibitor vorinostat has been shown to downregulate CXCR4 expression in MF cell lines, suggesting a potential therapeutic approach to modulate chemokine receptor-mediated tumor progression (90). This evidence concerns the gene CXCR4 and neoplasm.